Financial Data and Key Metrics Changes - The company's total revenue for the first three quarters of 2025 reached RMB 32.86 billion, with revenue from continuing operations growing 22.5% year-over-year to RMB 32.45 billion [5] - Adjusted non-IFRS net profit increased by 43.4% to RMB 10.54 billion, with a non-IFRS net profit margin improving to 32.1% [5][17] - The adjusted non-IFRS gross profit margin improved from 41.6% in 2024 to 47% in 2025 [17] Business Line Data and Key Metrics Changes - WuXi Chemistry's revenue grew 29.3% to RMB 25.98 billion, with an adjusted non-IFRS gross profit margin improving 5.8 percentage points year-over-year to 51.3% [6][7] - WuXi TIDES revenue surged 121.1% year-over-year to RMB 7.84 billion, with a backlog growth of 17.1% [8] - WuXi Testing revenue remained flat at RMB 4.17 billion, while lab testing services revenue grew 7.2% year-over-year [11][12] Market Data and Key Metrics Changes - Revenue from the U.S. region grew 31.9%, while Europe saw a 13.5% increase, and revenue from China remained relatively flat [6] - The company's backlog for continuing operations reached a record RMB 59.88 billion, growing 41.2% year-over-year [5][6] Company Strategy and Development Direction - The company plans to focus on its core CRDMO business model and accelerate global expansion, capacity construction, and capability development [21][23] - A strategic decision was made to sell 100% of its China-based clinical research services business to Hillhouse Investment Management, which will be classified as a discontinued operation [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in continuing operations revenue for 2025, raising the growth rate expectation to 17% to 18% [23][24] - The company anticipates total revenue for 2025 to be between RMB 43.5 billion and RMB 44.0 billion, up from previous guidance [24] Other Important Information - The company has implemented a total of RMB 6.88 billion in cash dividends, share repurchases, and cancellations, representing over 70% of the company's net profit in 2024 [25] - The company is actively advancing global capacity expansion, with CapEx payments reaching RMB 3.57 billion in the first three quarters [19] Q&A Session Summary Question: What has been driving the backlog growth, particularly in the small molecule part? - The backlog growth is mainly driven by contributions from small molecule DNM, especially from late-stage clinical and commercial projects [30] Question: What has been driving the high gross margin in the third quarter? - The high margin is attributed to continuous optimization of the manufacturing process and an increase in late-phase and commercial projects, improving utilization efficiency [34] Question: How do U.S. customers view the new BioSecure bill? - Customers have not shown a significant change in demand patterns, and the company continues to meet service demands effectively [40] Question: Does the raised guidance for the full year include the clinical research services business? - The guidance for continuing operations has excluded the clinical research services business, which will be reclassified as discontinued operations [45] Question: What is the outlook for early-stage demand? - There has been a rise in early-stage demand, particularly from U.S. customers, driven by the company's differentiated capabilities [47] Question: What are the key drivers in the small molecule CDMO business? - The small molecule pipeline includes multiple potential big projects, including GLP-1 and other therapeutic areas [60]

Financial Data and Key Metrics Changes - Total company revenues increased by 2.6% to $255 million, or 4.4% on a constant currency basis compared to Q1 2024 [5][13] - Adjusted EBITDA increased by 8.8% to $122 million, equating to an 11.2% growth rate on a constant currency basis [5][15] - Adjusted EPS improved to $0.14 per share, a $0.01 increase versus Q1 2024 [5][16] - Net loss on a GAAP basis was $13 million, or $0.05 per diluted share, compared to a net income of $6 million, or $0.02 per diluted share in Q1 2024 [15][16] Business Line Data and Key Metrics Changes - **Sterigenics**: Revenue grew by 1.9% to $170 million, or 3.9% on a constant currency basis, with segment income increasing by 2.5% to $88 million [17][18] - **Nordion**: Revenue surged by 36% to $33 million, or 40.6% on a constant currency basis, with segment income increasing approximately 62% to $17.4 million [18][19] - **Nelson Labs**: Revenue declined by 9.3% to $52 million, but segment income increased by 7% to $60 million, driven by favorable volume and mix from improved core lab testing [20][21] Market Data and Key Metrics Changes - The company operates in a $4.5 billion sterilization service addressable market, with positive trends driven by an aging population, healthcare spending, product innovation, and stringent regulatory requirements [6] - The foreign currency presented a headwind of 180 basis points for the quarter, most pronounced in the Canadian-based Nordion business [13] Company Strategy and Development Direction - The company aims for revenue growth in the range of 4% to 6% and adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis for 2025 [9][22] - The strategic focus includes excellence in customer service, winning in growth markets, driving operational excellence, and disciplined capital deployment [28] - The company plans to prioritize organic growth and deleveraging, along with opportunistic M&A [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the recovery of Sterigenics and noted that volumes are expected to improve throughout the year [34][46] - The company does not anticipate current tariff policies to have a material impact on its business, with 85% of total revenue being service revenue [9][23] - Management reaffirmed the outlook for 2025, indicating that the foreign exchange headwind has improved compared to previous estimates [22] Other Important Information - The company has $715 million of available liquidity, including over $300 million of unrestricted cash [21] - Capital expenditures for Q1 2025 totaled $20 million, with expectations for full-year capital expenditures in the range of $190 million to $210 million [21][26] Q&A Session Summary Question: Impact of tariffs on the business - Management expressed confidence that current regulations will not have a material impact on the company, particularly regarding cobalt shipments from Canada to the U.S. [31][32] Question: Volume recovery in Sterigenics and Nelson - Management noted optimism regarding volume improvements in both Sterigenics and Nelson Labs, supported by strong customer survey results [34][35] Question: Nelson Labs margin trends - Management highlighted that new regulations and product spend are driving improvements in margins, with expectations for continued growth throughout the year [40][41] Question: Legal strategy and ongoing cases - Management stated confidence in their legal strategy and ability to defend against claims, emphasizing the importance of scientific evidence [50][52] Question: Cross-selling initiatives between Nelson and Sterigenics - Management confirmed ongoing incentives for cross-selling and noted positive customer responses to integrated services [53][55] Question: Pricing levels and customer pushback - Management indicated that pricing for Sterigenics remains consistent with long-term targets, with ongoing discussions with customers about value delivery [75][78]